## DIVISION OF CORPORATION FINANCE

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

Mail Stop 3561

June 9, 2017

Via E-mail Christopher Missling, PhD Chief Executive Officer Anavex Life Sciences Corp. 51 West 52nd Street, 7th Floor New York, NY 10019-6163

**Re:** Anavex Life Sciences Corp.

**Registration Statement on Form S-3** 

Filed May 26, 2017 File No. 333-218292

Dear Dr. Missling:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Hillary Daniels at (202) 551-3959 with any questions.

Sincerely,

/s/ Pamela Howell for

John Reynolds Assistant Director Office of Beverages, Apparel, and Mining

cc: Clayton E. Parker, Esq. K&L Gates LLP